Holding(s) in Company

RNS Number : 2637G
N4 Pharma PLC
16 March 2020
 

16 March 2020

 

N4 Pharma plc

("N4 Pharma", the "Company" or the "Group")

 

Holding in Company

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for vaccines and cancer treatments, has been notified today that, as of 26 July 2019, First Equity Limited no longer had a notifiable interest in the issued share capital of the Company.

 

Enquiries:

 

N4 Pharma Plc

Nigel Theobald, CEO

 

 

Via Scott PR

Allenby Capital Limited

James Reeve/Asha Chotai

 

Tel: +44(0)203 328 5656

Scott PR

Georgia Smith

 

Tel: +44(0)1477 539 539

 

About N4 Pharma

 

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

 

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLFLFFIVFIRLII

Companies

N4 Pharma (N4P)
UK 100

Latest directors dealings